|
Malignant Neoplasms
|
0.400 |
CausalMutation
|
group |
CGI |
|
|
|
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1.
|
21471201 |
2011 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
FRAP kinetics showed a highly significant increase in the recovery of photobleached CapG-eGFP in the cancer cells, so that a differentiation of invasive, metastasizing cells and non-invasive, non-metastasizing cells on the basis of transport processes of the CapG protein between the nucleus and the cytoplasm seems to be possible.
|
18059028 |
2008 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) regulates cellular processes important for progression of human cancer.
|
19372546 |
2009 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) inhibitors such as rapamycin have shown modest effects in cancer therapy due in part to the removal of a negative feedback loop leading to the activation of the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) signaling pathway.
|
20392999 |
2010 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) inhibitors have been clinically used as anticancer agents in several types of human malignancies including neuroendocrine tumor (NET) but the development of clinical resistances or their therapeutic limitations have been also reported.
|
22178087 |
2012 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) is an evolutionarily conserved protein kinase. mTOR forms two distinct functional multiprotein kinase complexes that mutually phosphorylate different substrates and regulate a wide array of essential cellular processes including translation, transcription and autophagy. mTOR is active in several types of cancer and plays a role in a variety of other serious human diseases, including diabetes, neurodegenerative disorders and polycystic kidney disease.
|
22388550 |
2012 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin complex 1 (mTORC1) signaling is frequently dysregulated in cancer.
|
22474287 |
2012 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mammalian target of rapamycin complex 1 (mTORC1) plays an important role in maintaining proper cellular functions, and genetic variations in this complex may affect cancer risk.
|
23423739 |
2013 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) acts as a hub integrating signals from nutrient availability and growth factors and plays central roles in regulating protein synthesis and cell growth, which has been validated as a promising target for cancer therapy.
|
24018642 |
2014 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MTOR complex-1(mTORC1) activation occurs frequently in cancers, yet clinical efficacy of rapalogs is limited because of the associated activation of upstream survival pathways.
|
25061101 |
2014 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) is a protein kinase that regulates cellular proliferation. mTOR inhibitors are used in cancer patients and recently found to be effective in the treatment of insulinoma and HH patients.
|
25518065 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) pathway is known to be involved in cancer pathogenesis.
|
25776026 |
2015 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) activation is one of the most frequent events in human malignancies, and is critical for sustaining the self‑renewing ability of cancer stem cells (CSCs); inhibition by rapamycin is an effective and promising strategy in anticancer treatments.
|
26707081 |
2016 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) inhibitors exert significant antitumor effects on several cancer cell types.
|
27492819 |
2016 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) gene polymorphisms exert the major effects on the regulation of transcriptional activity and miRNA binding or splicing, which may be associated with cancer risk by affecting mTOR gene expression.
|
27533457 |
2016 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mechanistic target of rapamycin complex 1 (mTORC1) controls biosynthesis and has been implicated in uncontrolled cell growth in cancer.
|
28069808 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) is one of the most important targets for treatment of cancer, specifically for breast and lung cancer.
|
28577112 |
2017 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) plays a critical role in the regulation of tumor cell motility, invasion and cancer cell metastasis. mTOR consists of two separate multi-protein complexes, mTOR complex (mTORC) 1 and mTORC2.
|
29491094 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian Target of Rapamycin 1 (mTORC1) inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy.
|
29729190 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting.
|
29848950 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin (mTOR) has a pivotal role in carcinogenesis and cancer cell proliferation in diverse human cancers.
|
30887599 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Mammalian target of rapamycin complex 2 (mTORC2) has been implicated in cancer by regulating multiple AGC kinases, especially AKT proteins.
|
31062368 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A key target of PA is the mammalian target of rapamycin (mTOR), a serine-threonine kinase that has been widely implicated in cancer cell survival signals.
|
20438709 |
2010 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A total of 26 of these miRNAs targeted genes involved in pathways connected to the three main features of SSc and to cancer development including Epidermal growth factor (EGF) receptor, ErbB1 downstream, Sphingosine 1 phosphate receptor 1 (S1P1), Activin receptor-like kinase 1 (ALK1), Endothelins, Ras homolog family member A (RhoA), Class I Phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), p38 mitogen-activated protein kinase (MAPK), Ras-related C3 botulinum toxin substrate 1 (RAC1), Transforming growth factor (TGF)-beta receptor, Myeloid differentiation primary response 88 (MyD88) and Toll-like receptors (TLRs) pathways.
|
30866419 |
2019 |